Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
A philosophy professor is coralled into an erratic reckoning with a terrible act in his past in a sincere and oddly absorbing attempt to turn an off-puttingly controversial issue into a ...
Jack Huston, Sofia Boutella and Daniel Zavatto star in the octogenarian’s new feature, a morally complex study of past sin affecting present life. By Richard Lawson When Paul Schrader’s new moral ...
The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...
Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC. In the phase 1/2 trial, daraxonrasib ...
MSK gastrointestinal medical oncologist Eileen O'Reilly, MD (left), led a very promising early phase clinical trial of the targeted RAS therapy daraxonrasib for people facing pancreatic cancer.
Add the following CSS to the header block of your HTML document. Then add the mark-up below to the body block of the same document. .videoWrapper { position: relative; padding-bottom: 56.25%; ...